CatalystWireBeta

UK small-cap RNS · 26 Jan 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus the ones that are part of a situation. Not investment advice.

TimeCompanyMcap ↕TypeAnnouncement
16:45 Coro Energy CORO £3.1m Overhang Holding(s) in Company
16:32 Mode Global Holdings MODE £0.5m Legal & regulatory Unaudited interim results
The Company is pleased to announce its unaudited interim results for the six months ended 30
07:03 Quantum Helium Limited QHE £7.7m Project milestones BIA Approval of Irrevocable Letter of Credit
Quantum Helium Limited (AIM: QHE) is pleased to announce that the Irrevocable Letter of Credit ("ILOC") required for bonding has now been formally approved by the U.S.
07:00 Nanoco Group NANO £4.8m Turnaround plan with targets Conclusion of CDX process & Directorate changes
Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from its technology platform, announces that, following an extensive exercise in relation to a potential …
07:00 Georgina Energy plc GEX £27m Project milestones Hussar EP513 Drilling/Funding
Georgina Energy Plc, GEX.L advises Harlequin Energy Ltd ('Harlequin') has formally confirmed its intention to proceed with funding for the Hussar EP513 prospect for the anticipated recovery of Helium, Hydrogen and Natural Gas.
07:00 Kavango Resources KAV £28m Project milestones Successful Diamond Drilling at Bill’s Luck
Successful diamond resource drilling programme at Bill's Luck Gold Mine
07:00 Costain Group COST £651m Capital return New Pension Scheme Agreement & FY25 Trading Update
Update on New Pension Scheme Agreement, Enhanced Shareholder Returns and FY 25 Trading
07:00 Venture Life Group VLG £80m Capital return Trading Update
Venture Life (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, announces a trading update for the twelve-month period ended 31 December 2025 (the "Period").
07:00 Scancell Holdings SCLP £124m Project milestones FDA clearance of IND application for iSCIB1+
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note